Welcome to clinical site selection and evaluation Part 2, where we continue the conversation on optimizing clinical site selection and evaluation. In this episode Linda Peterson and Julie Sheidy share recommendations on how to approach site selection, how to build teams, how to communicate within organizations and across teams, and their approach to site identification.
Key takeaways include:
3:00 – How can the site and sponsor work together to accelerate site selection?
5:15 – Julie describes the traits, skills, and characteristics of a “dream team” from CRO or Sponsor perspective and from the site’s perspective.
8:45 – In the event that a CRO or Sponsor identifies a lack of resources at a particular site, is there an advantage to the CRO or Sponsor supplementing those resources?
10:50 – The importance of strong communication within and between the CRO and site “dream teams.”
14:15 – Tips for maintaining a good working relationship and culture through turnover or staffing changes.
16:30 – Best practices for site identification and site selection in the case of rare disease trials and/or common chronic disease trials.
19:15 – How do you address potential site-related bias or the impact of advanced expertise when considering major center or world-class research institutions? How do you ensure the findings are applicable to all care settings if you are conduct research at elite institutions?
20:15 – Can or should sites advocate for altering a protocol or research question to better fit the population or their specific patient population?
Ready to take your technical writing to the next level, but not sure where to start? Would you like to learn some tips to...
We are excited to announce the launch of the official Global Regulatory and Consulting Blog. To celebrate the release of the first blog posts...
In this episode of Chasing Compliance, host Jamie Hijmans sits down with Carrie Eklund, Senior Manager of Chemistry, Manufacturing, and Controls or CMC at...